Technical Analysis for EYPT - EyePoint Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 8.87 0.11% 0.01
EYPT closed up 0.11 percent on Friday, May 14, 2021, on 85 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical EYPT trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup 0.11%
Narrow Range Bar Range Contraction 0.11%
NR7 Range Contraction 0.11%
NR7-2 Range Contraction 0.11%
Wide Bands Range Expansion 0.11%
Older End-of-Day Signals for EYPT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 12 hours ago
Rose Above Previous Day's High about 15 hours ago
Up 2% about 15 hours ago
1.5x Volume Pace about 16 hours ago
Up 1% about 16 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

EyePoint Pharmaceuticals, Inc. Description

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Eye Organic Compounds Inflammation Ophthalmic Macular Degeneration Related Macular Degeneration Suspension Tyrosine Kinase Macular Edema Eye Disease Wet Age Related Macular Degeneration Chronic Disease Diabetic Macular Edema Chronic Diseases Retinitis Eye Diseases Glucocorticoids Uveitis Ophthalmic Product Ophthalmic Products Pregnanes Alimera Sciences Cytomegalovirus Retinitis Dexamethasone Diketones Fluocinolone Psivida

Is EYPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.0599
52 Week Low 3.511
Average Volume 219,646
200-Day Moving Average 7.73
50-Day Moving Average 10.09
20-Day Moving Average 9.74
10-Day Moving Average 9.55
Average True Range 0.71
ADX 19.27
+DI 14.67
-DI 24.20
Chandelier Exit (Long, 3 ATRs ) 9.09
Chandelier Exit (Short, 3 ATRs ) 10.73
Upper Bollinger Band 11.28
Lower Bollinger Band 8.20
Percent B (%b) 0.22
BandWidth 31.57
MACD Line -0.33
MACD Signal Line -0.19
MACD Histogram -0.1414
Fundamentals Value
Market Cap 1.27 Billion
Num Shares 144 Million
EPS -0.72
Price-to-Earnings (P/E) Ratio -12.30
Price-to-Sales 1.79
Price-to-Book 10.19
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.46
Resistance 3 (R3) 9.47 9.30 9.36
Resistance 2 (R2) 9.30 9.15 9.29 9.32
Resistance 1 (R1) 9.08 9.06 9.00 9.07 9.29
Pivot Point 8.91 8.91 8.86 8.90 8.91
Support 1 (S1) 8.69 8.76 8.61 8.68 8.45
Support 2 (S2) 8.52 8.67 8.51 8.42
Support 3 (S3) 8.30 8.52 8.38
Support 4 (S4) 8.29